0001104659-23-061379.txt : 20230516 0001104659-23-061379.hdr.sgml : 20230516 20230516160707 ACCESSION NUMBER: 0001104659-23-061379 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20230516 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230516 DATE AS OF CHANGE: 20230516 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ANI PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001023024 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 582301143 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-31812 FILM NUMBER: 23927507 BUSINESS ADDRESS: STREET 1: 210 MAIN STREET WEST CITY: BAUDETTE STATE: MN ZIP: 56623 BUSINESS PHONE: 2186343500 MAIL ADDRESS: STREET 1: 210 MAIN STREET WEST CITY: BAUDETTE STATE: MN ZIP: 56623 FORMER COMPANY: FORMER CONFORMED NAME: BIOSANTE PHARMACEUTICALS INC DATE OF NAME CHANGE: 19991228 FORMER COMPANY: FORMER CONFORMED NAME: BEN ABRAHAM TECHNOLOGIES INC DATE OF NAME CHANGE: 19991027 8-K 1 tm2315239d6_8k.htm FORM 8-K
0001023024 false 0001023024 2023-05-16 2023-05-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

 

FORM 8-K 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of Earliest Event Reported): May 16, 2023

 

ANI PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware 001-31812 58-2301143
(State or other jurisdiction of
incorporation)		 (Commission File Number) (I.R.S. Employer Identification No.)

 

210 Main Street West

Baudette, Minnesota

   56623
(Address of principal executive offices)   (Zip Code)

 

Registrant's telephone number, including area code: (218) 634-3500

 

Not Applicable
(Former name or former address, if changed since last report.)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which
registered
Common Stock ANIP Nasdaq Stock Market

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging Growth Company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

  

 

 

Item 8.01 Other Events

 

On May 16, 2023, ANI Pharmaceuticals, Inc., a Delaware corporation (the “Company”) issued a press release announcing that it has completed the sale of 2,183,545 shares of its common stock, $0.0001 par value per share (the “Common Stock”) at a public offering price of $39.50 per share, inclusive of the exercise in full of the underwriters’ option to purchase an additional 284,810 shares of Common Stock, pursuant to the Underwriting Agreement entered into by and between the Company and Guggenheim Securities, LLC, as representative of the several underwriters named therein. The Company received gross proceeds of approximately $86.25 million before deducting the underwriting discounts and commissions and estimated fees and expenses payable by the Company in connection with offering. A copy of the Company’s press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

Item 9.01 Exhibits

 

(d) Exhibits

 

Exhibit No. Description
5.1 Opinion of Morgan, Lewis & Bockius LLP
23.1 Consent of Morgan, Lewis & Bockius LLP (included in Exhibit 5.1)
99.1 Press Release of the Company, dated May 16, 2023
104 Cover Page Interactive Data File (embedded with the Inline XBRL document)

  

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: May 16, 2023 ANI PHARMACEUTICALS, INC.
     
  By: /s/ Stephen P. Carey
  Name: Stephen P. Carey
  Title: Senior Vice President Finance and Chief Financial Officer

 

 

 

 EX-5.1 2 tm2315239d6_ex5-1.htm EXHIBIT 5.1

 

Exhibit 5.1

 

 

 

May 16, 2023

 

ANI Pharmaceuticals, Inc.
210 Main Street West
Baudette, Minnesota

 

Re:ANI Pharmaceuticals, Inc. Registration Statement on Form S-3 (333-239771)

 

Ladies and Gentlemen:

 

We have acted as counsel for ANI Pharmaceuticals, Inc., a Delaware corporation (the “Company”), in connection with the offering and sale by the Company of 2,183,545 shares (the “Shares”) of common stock, $0.0001 par value per share, of the Company (the “Common Stock”) pursuant to that certain Underwriting Agreement, dated May 11, 2023, by and between the Company and Guggenheim Securities, LLC, as representative of the several underwriters named therein (the “Underwriting Agreement”).

 

As to all matters of fact (including factual conclusions and characterizations and descriptions of purpose, intention or other state of mind), we have relied, with your permission, entirely upon actions by the Board of Directors of the Company and certificates of certain officers of the Company and have assumed, without independent inquiry, the accuracy of those certificates and written actions by the Board of Directors of the Company.

 

As counsel to the Company, in rendering the opinions hereinafter expressed, we have examined and relied upon originals or copies of such corporate records, agreements, documents and instruments as we have deemed necessary or advisable for purposes of this opinion, including (i) the certificate of incorporation and bylaws of the Company, each as amended to date, (ii) the Company’s registration statement on Form S-3 (Registration No. 333-239771) (the “Registration Statement”) filed by the Company with the Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended (the “Securities Act”), which was declared effective on July 17, 2020, (iii) the Prospectus Supplement, dated May 11, 2023, filed by the Company with the Commission on May 12, 2023 and the accompanying base prospectus, (iv) the Underwriting Agreement and (v) the actions of the Board of Directors of the Company referenced above.

 

This opinion is limited solely to the Delaware General Corporation Law without regard to choice of law, to the extent that the same may apply to or govern the transactions contemplated by the Registration Statement. We express no opinion as to the effect of events occurring, circumstances arising, or changes of law becoming effective or occurring, after the date hereof on the matters addressed in this opinion.

 

  Morgan, Lewis & Bockius LLP
   
  502 Carnegie Center +1.609.919.6600
  Princeton, NJ 08540-6241 +1.609.919.6701
  United States

 

 

 

 

 

ANI Pharmaceuticals, Inc.

May 16, 2023

Page 2

 

Based on such examination and subject to the foregoing, we are of the opinion that the Shares, when issued by the Company and delivered by the Company against payment therefor as contemplated by and in accordance with the procedures set forth in the Underwriting Agreement, will be validly issued, fully paid and non-assessable.

 

We hereby consent to the filing of this opinion letter as Exhibit 5.1 to the Registration Statement and to the reference to us under the caption “Legal Matters” in the Prospectus. In giving this consent, we do not admit that we are in the category of persons whose consent is required under Section 7 of the Act, or the rules and regulations of the Commission thereunder. In rendering this opinion, we are opining only as to the specific legal issues expressly set forth herein, and no opinion shall be inferred as to any other matter or matters. This opinion is intended solely for use in connection with the issuance and sale of the Shares subject to the Registration Statement and is not to be relied upon for any other purpose.

 

  Very truly yours, 
  /s/ Morgan, Lewis & Bockius LLP

 

 

 

 EX-99.1 3 tm2315239d6_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

ANI PHARMACEUTICALS ANNOUNCES CLOSING OF PUBLIC OFFERING OF COMMON STOCK INCLUDING FULL EXERCISE OF UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES

 

BAUDETTE, Minn.— (BUSINESS WIRE) – May 16, 2023 — ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (“ANI” or the “Company”) today announced the closing of its previously announced underwritten public offering. A total of 2,183,545 shares of its common stock were sold at a public offering price of $39.50 per share, inclusive of the exercise in full of the underwriters’ option to purchase an additional 284,810 shares of common stock. The gross proceeds of the offering to the Company are approximately $86.25 million, before deducting the underwriting discounts and commissions and offering expenses.

 

Guggenheim Securities, LLC acted as lead book-running manager for the offering. Truist Securities also acted as a book-runner for the offering. H.C. Wainwright & Co. acted as lead manager for the offering.

 

The securities described above were offered by ANI pursuant to a shelf registration statement on Form S-3 (File No. 333-239771), which was filed by the Company with the Securities and Exchange Commission (the “SEC”) on July 9, 2020 and was declared effective by the SEC on July 17, 2020.

 

A preliminary prospectus supplement and a final prospectus supplement relating to the offering were filed with the SEC on May 11, 2023 and May 12, 2023, respectively, and are available on the SEC’s website at http://www.sec.gov. Copies of the final prospectus supplement and accompanying prospectus relating to the offering may be obtained from Guggenheim Securities, LLC Attention: Equity Syndicate Department, 330 Madison Avenue, New York, NY 10017 or by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com or from Truist Securities, Inc., Attention: Prospectus Department, 3333 Peachtree Road NE, 9th floor, Atlanta, Georgia 30326, by telephone at (800) 685-4786, or by email at TruistSecurities.prospectus@Truist.com.

 

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

 

About ANI Pharmaceuticals, Inc.

 

ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified bio-pharmaceutical company serving patients in need by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need. Our team is focused on delivering sustainable growth by building a successful Purified Cortrophin® Gel franchise, strengthening our generics business with enhanced development capability, innovation in established brands and leveraging our North American manufacturing capabilities.

 

Investor Relations:

 

Lisa M. Wilson, In-Site Communications, Inc.

 

T: 212-452-2793

 

E: lwilson@insitecony.com

 

Source: ANI Pharmaceuticals, Inc.

 

 

 

 EX-101.SCH 4 anip-20230516.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 anip-20230516_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 anip-20230516_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 tm2315239d6_ex5-1img001.jpg GRAPHIC begin 644 tm2315239d6_ex5-1img001.jpg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end GRAPHIC 8 tm2315239d6_ex5-1img002.jpg GRAPHIC begin 644 tm2315239d6_ex5-1img002.jpg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end GRAPHIC 9 tm2315239d6_ex5-1img003.jpg GRAPHIC begin 644 tm2315239d6_ex5-1img003.jpg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end XML 10 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Cover
May 16, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 16, 2023
Entity File Number 001-31812
Entity Registrant Name ANI PHARMACEUTICALS, INC.
Entity Central Index Key 0001023024
Entity Tax Identification Number 58-2301143
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 210 Main Street West
Entity Address, City or Town Baudette
Entity Address, State or Province MN
Entity Address, Postal Zip Code 56623
City Area Code 218
Local Phone Number 634-3500
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol ANIP
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 11 tm2315239d6_8k_htm.xml IDEA: XBRL DOCUMENT 0001023024 2023-05-16 2023-05-16 iso4217:USD shares iso4217:USD shares 0001023024 false 8-K 2023-05-16 ANI PHARMACEUTICALS, INC. DE 001-31812 58-2301143 210 Main Street West Baudette MN 56623 218 634-3500 Common Stock ANIP NASDAQ false false false false false EXCEL 12 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 13 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 14 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 15 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://anipharmaceuticals.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2315239d6_8k.htm anip-20230516.xsd anip-20230516_lab.xml anip-20230516_pre.xml tm2315239d6_ex5-1.htm tm2315239d6_ex99-1.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 17 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2315239d6_8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2021q4": 22 }, "contextCount": 1, "dts": { "inline": { "local": [ "tm2315239d6_8k.htm" ] }, "labelLink": { "local": [ "anip-20230516_lab.xml" ] }, "presentationLink": { "local": [ "anip-20230516_pre.xml" ] }, "schema": { "local": [ "anip-20230516.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "anip", "nsuri": "http://anipharmaceuticals.com/20230516", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2315239d6_8k.htm", "contextRef": "From2023-05-16to2023-05-16", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://anipharmaceuticals.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2315239d6_8k.htm", "contextRef": "From2023-05-16to2023-05-16", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://anipharmaceuticals.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 18 0001104659-23-061379-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-061379-xbrl.zip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end